The Japanese pharmaceutical market is the second largest individual market after the US. Its annual sales of some $60 billion constitute approximately 11% of the world market. Equateq’s proprietorial Maxomega technology allows it to deliver the highest concentration levels possible in the sector, at up to 99% purity of a single lipid. The facility has been a site of lipid concentration for nearly 30 years, and is certified as cGMP by the UK’s health authority, the MHRA.